Abstract
Hypertension is risk factor for cardiovascular morbidity and mortality, and stroke. A critical surge in blood pressure occurs during the early morning hours coincident with increased incidences of myocardial infarction, unstable angina, stroke and sudden cardiac death. This suggests that, in patients with hypertension, it may be important to maintain the efficacy of antihypertensive medication over the 24-h dosing interval, especially in the risky early morning hours. In order to evaluate the antihypertensive efficacies of fixed-dose combinations of angiotensin II receptor blockers with hydrochlorothiazide (HCTZ) 12.5 mg, a multicenter, randomized, prospective, open-label, blinded-endpoint study was performed in 805 patients with mild-to-moderate hypertension randomized to once-daily treatment with telmisartan 40 mg plus HCTZ (T40/H12.5), losartan 50 mg plus HCTZ (L50/H12.5), or telmisartan 80 mg plus HCTZ (T80/H12.5), with the primary objective of comparing T40/H12.5 with L50/H12.5 and evaluating the additional response of T80/H12.5. Efficacy was assessed by ambulatory blood pressure monitoring (ABPM), clinic seated cuff sphygmomanometry and calculated responder rates after 6 weeks' active treatment. The primary endpoint was reduction from baseline in the last 6-h mean (relative to dosing) diastolic blood pressure (DBP) measured using 24-h ABPM. Compared with the L50/H12.5 group, the mean reductions in the last 6-h mean DBP for the T40/H12.5 and T80/H12.5 groups were significantly greater: -2.0 mmHg (p=0.0031) and -2.8 mmHg (p=0.0003), respectively. We conclude that T40/H12.5 provided clinically and statistically significantly superior blood pressure reductions compared with L50/H12.5 during the last 6 h of the 24-h dosing interval, which corresponds to the high-risk early-morning hours, and that T80/H12.5 provided additional blood pressure reductions.
Similar content being viewed by others
Article PDF
References
Guidelines Subcommittee : 1999 World Health Organization—International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183.
Chobanian AV, Bakris GL, Black HR, et al: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.
Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–838.
Lewington S, Clarke R, Qizilbash N, Petro R, Collins R : Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.
White WB : Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001; 6: 63–72.
Muller JE, Ludmer PL, Willich SN, et al: Circadian variation in the frequency of sudden cardiac death. Circulation 1987; 75: 131–138.
Muller JE, Stone PH, Turi ZG, et al: Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313: 1315–1322.
Mulcahy D, Keegan J, Cunningham D, et al: Circadian variation of total ischaemic burden and its alteration with anti-anginal agents. Lancet 1988; 2: 755–759.
Mancia G, Parati G : Ambulatory blood pressure monitoring and organ damage. Hypertension 2000; 36: 894–900.
Quyyumi AA : Circadian rhythms in cardiovascular disease. Am Heart J 1990; 120: 726–733.
Timmermans PB : Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res 1999; 22: 147–153.
Siragy HM : Angiotensin receptor blockers: how important is selectivity? Am J Hypertens 2002; 15: 1006–1014.
Stangier J, Su C-APF, Roth W : Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28: 149–167.
Lo MW, Goldberg MR, McCrea JB, et al: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641–649.
Christen Y, Waeber B, Nussberger J, et al: Oral administration of DuP 753a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83: 1333–1342.
Stangier J, Su C-APF, van Heiningen PNM, et al: Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol 2001; 38: 672–685.
Goa KL, Wagstaff AJ : Losartan potassium: a review of its pharmacology, clinical efficacy, and tolerability in the management of hypertension. Drugs 1996; 51: 820–845.
Uchida H, Nakamura Y, Kaihara M, et al: Practical efficacy of telmisartan for decreasing morning blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545–550.
Guidelines Committee : 2003 European Society of Hypertension—European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Waeber B : Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther 2003; 1: 43–50.
Smith DH, Neutel JM, Lacourcière Y, Kempthorne-Rawson J : Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 2003; 21: 1237–1239.
American Society of Hypertension : Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens 1992; 5: 207–209.
Sharpe M, Jarvis B, Goa KL : Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501–1529.
Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R : Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27: 457–464.
Mallion J, Siche J, Lacourcière Y : ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657–664.
Lacourcière Y, Gil-Extremera B, Mueller O, et al: Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57: 273–279.
Elliott HL : Angiotensin II antagonists: efficacy, duration of action, comparison with other drugs. J Hum Hypertens 1998; 12: 271–274.
Gradman AH, Arcuri KE, Goldberg AI, et al: A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345–1350.
Messerli FH : … and losartan was no better than placebo. J Hum Hypertens 1999; 13: 649–650.
Burnier M, Maillard M : The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001; 10 ( Suppl 1): 6–11.
Clement DL, De Buyzere ML, De Bacquer DA, et al: Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407–2415.
Kario K, Pickering TG, Umeda Y, et al: Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401–1406.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Neutel, J., Littlejohn, T., Chrysant, S. et al. Telmisartan/Hydrochlorothiazide in Comparison with Losartan/Hydrochlorothiazide in Managing Patients with Mild-to-Moderate Hypertension. Hypertens Res 28, 555–563 (2005). https://doi.org/10.1291/hypres.28.555
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.28.555
Keywords
This article is cited by
-
A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure
Hypertension Research (2013)
-
What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?
Cardiovascular Diabetology (2012)
-
Effect of placebo on ambulatory blood pressure monitoring in children
Pediatric Nephrology (2012)
-
Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide
Hypertension Research (2009)